SMC
AARD

Smith, Moore & Co’s Aardvark Therapeutics AARD Stock Holding History

Smith, Moore & Co’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Buy
+20,000
New +$93.5K 0.01% 574

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $732M AUM 275.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return

Smith, Moore & Co's AARD Position: Q2 2026 in Review

Smith, Moore & Co opened a new position in Aardvark Therapeutics (AARD) in Q2 2026: 20,000 shares worth $115K. The stake represents 0.01% of the portfolio and ranks #574 among its holdings.

72 funds tracked by Wall St. Rank hold AARD as of Q2 2026.

  • Smith, Moore & Co held 20,000 shares of Aardvark Therapeutics worth $115K as of Q2 2026.
  • Aardvark Therapeutics was a new Smith, Moore & Co position in Q2 2026.
  • Aardvark Therapeutics made up 0.01% of Smith, Moore & Co's portfolio in Q2 2026, its #574 holding.
  • 72 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q2 2026.

Based on Smith, Moore & Co's 13F filing for Q2 2026, filed 12 Aug 2026.